2007-2009年抗肿瘤药全国医院市场分析

Analysis of Hospital Market of Anticancer Drugs from 2007 to 2009

目的:了解我国2007-2009年抗肿瘤药医院市场状况,为临床用药提供参考。方法:利用"全国医药经济信息网"提供的2007-2009年抗肿瘤药医院市场的销售金额、数量等数据,采用世界卫生组织推荐的限定日剂量等为指标进行统计分析。结果:抗肿瘤药销售金额年均增长率约为36.27,用药频度也逐年大幅增长;多西他赛、紫杉醇、奥沙利铂的销售金额排名前3,销售金额年均增长率分别为37.28、27.97、23.98;制药企业中以罗氏集团的医院市场占有份额最多,3年均超过总销售金额1/5;天然抗肿瘤药、抗代谢药和单克隆抗体药物增长最明显。结论:抗肿瘤药医院市场呈现快速增长趋势,其中新型抗肿瘤药及天然抗肿瘤药具有良好的应用前景。

OBJECTIVE：To evaluate the hospital market reference for rational use of drugs in the clinic. METHODS ： situation of anticancer drugs use from 2007 to 2009, and to provide By defined daily dose （DDD） recommended by WHO as index, the consumption sum and amount of anticancer drugs from 2007 to 2009 collected from ＂State Medicine Economy Information Network＂ were analyzed statistically. RESULTS： The consumption sum and DDDs of anticancer drugs were increased significantly year by year. The annual increasing rate of consumption sum was 36.27%. Docetaxel, paclitaxel, oxaliplatin were the top three in the list of consumption sum, and annual increasing rates of consumption sum were 37.28%, 27.97%, 23.98% , respectively. Roche pharmaceutical enterprise dominated the first place of hospital market, its consumption sum accounted for one fifth of total consumption sum. The consumption sum of natural anticaneer drugs, antimetabolite and monoclonal antibody increased significantly. CONCLUSION： The anticancer drugs present rapid increasing tendency, especially new types of anticancer drugs and natural anticancer drugs.